Research & Literature

Intracranial aneurysm in a patient with glucocorticoid-remediable aldosteronism.

Al Romhain B, Young AM, Battacharya JJ, Suttner N

British journal of neurosurgery 2015; (29(5)):715-7 doi:10.3109/02688697.2015.1023775.

An Update on Familial Hyperaldosteronism.

Korah HE, Scholl UI

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2015; (47(13)):941-6 doi:10.1055/s-0035-1564166.

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.

Strehl C, Bijlsma JW, de Wit M, et al.

Annals of the rheumatic diseases 2016; (75(6)):952-7 doi:10.1136/annrheumdis-2015-208916.

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.

Bardet S, Chamontin B, Douillard C, et al.

Annales d'endocrinologie 2016; (77(3)):208-13.

SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps.

Douillard C, Houillier P, Nussberger J, Girerd X

Annales d'endocrinologie 2016; (77(3)):192-201.

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.

Zennaro MC, Jeunemaitre X

Annales d'endocrinologie 2016; (77(3)):214-9.

A Case of Glucocorticoid Remediable Aldosteronism and Thoracoabdominal Aneurysms.

Shahrrava A, Moinuddin S, Boddu P, Shah R

Case reports in endocrinology 2016; (2016()):2017571 doi:10.1155/2016/2017571.

Role of ACTH and Other Hormones in the Regulation of Aldosterone Production in Primary Aldosteronism.

El Ghorayeb N, Bourdeau I, Lacroix A

Frontiers in endocrinology 2016; (7()):72 doi:10.3389/fendo.2016.00072.

Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Gomez-Sanchez CE, Qi X, Gomez-Sanchez EP, et al.

Molecular and cellular endocrinology 2017; (439()):74-80 doi:10.1016/j.mce.2016.10.025.

DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

Lenders JWM, Williams TA, Reincke M, Gomez-Sanchez CE

European journal of endocrinology 2018; (178(1)):R1-R9.

Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.

Singh DN, Krishnamurthy S, Kamalanathan SK, et al.

Paediatrics and international child health 2018; (38(4)):251-260 doi:10.1080/20469047.2018.1505589.

Inherited Forms of Primary Hyperaldosteronism: New Genes, New Phenotypes and Proposition of A New Classification.

Perez-Rivas LG, Williams TA, Reincke M

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2019; (127(2-03)):93-99 doi:10.1055/a-0713-0629.

Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy.

Ward LM, Hadjiyannakis S, McMillan HJ, et al.

Pediatrics 2018; (142(Suppl 2)):S34-S42 doi:10.1542/peds.2018-0333E.

Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations.

Bowden SA, Connolly AM, Kinnett K, Zeitler PS

Journal of neuromuscular diseases 2019; (6(1)):31-41 doi:10.3233/JND-180346.

Family hyperaldosteronism type I: a clinical case and review of literature.

Chikladze NM, Favorova OO, Chazova IE

Terapevticheskii arkhiv 2018; (90(9)):115-122 doi:10.26442/terarkh2018909115-122.

Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy.

Izzo JL, Hong M, Hussain T, Osmond PJ

Journal of clinical hypertension (Greenwich, Conn.) 2019; (21(7)):922-928 doi:10.1111/jch.13567.

Adrenalectomy Completely Cured Hypertension in Patients With Familial Hyperaldosteronism Type I Who Had Somatic KCNJ5 Mutation.

Lin YF, Peng KY, Chang CH, et al.

The Journal of clinical endocrinology and metabolism 2019; (104(11)):5462-5466 doi:10.1210/jc.2019-00689.

Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism.

Izzo JL, Hong M, Hussain T, Osmond PJ

Journal of clinical hypertension (Greenwich, Conn.) 2019; (21(8)):1183-1190 doi:10.1111/jch.13597.

Molecular mechanisms in primary aldosteronism

De Sousa K, Abdellatif AB, El Zein RM, Zennaro MC

Journal of molecular endocrinology 2019; (242(3)):R67-R79 doi:10.1530/JOE-19-0193.

The management of glucocorticoid deficiency: Current and future perspectives.

Dineen R, Martin-Grace J, Thompson CJ, Sherlock M

Clinica chimica acta; international journal of clinical chemistry 2020; (505()):148-159 doi:10.1016/j.cca.2020.03.006.

Molecular Basis of Primary Aldosteronism and Adrenal Cushing Syndrome.

Vaduva P, Bonnet F, Bertherat J

Journal of the Endocrine Society 2020; (4(9)):bvaa075 doi:10.1210/jendso/bvaa075.

Taiwan mini-frontier of primary aldosteronism: Updating detection and diagnosis.

Chang CC, Chen YY, Lai TS, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(1 Pt 1)):121-129 doi:10.1016/j.jfma.2020.08.001.

Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone.

Sanga V, Lenzini L, Seccia TM, Rossi GP

Blood pressure 2021; (30(2)):133-137 doi:10.1080/08037051.2020.1863771.

[Hyperaldosteronism].

Scholl UI

Der Internist 2021; (62(3)):245-251 doi:10.1007/s00108-021-00972-8.

A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.

Sanga V, Seccia TM, Rossi GP

Endocrine 2021; (74(1)):5-10 doi:10.1007/s12020-021-02763-5.

Glucocorticoid induced adrenal insufficiency.

Prete A, Bancos I

BMJ (Clinical research ed.) 2021; (374()):n1380 doi:10.1136/bmj.n1380.

A Chinese pedigree with glucocorticoid remediable aldosteronism.

Liu X, Jin L, Zhang H, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2021; (44(11)):1428-1433 doi:10.1038/s41440-021-00685-3.

Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Cheng CY, Liao HW, Peng KY, et al.

Biomedicines 2021; (9(12)) doi:10.3390/biomedicines9121816.

GRAde: a long-read sequencing approach to efficiently identifying the CYP11B1/CYP11B2 chimeric form in patients with glucocorticoid-remediable aldosteronism.

Wu YC, Chen CI, Chen PY, et al.

BMC bioinformatics 2022; (22(Suppl 10)):613 doi:10.1186/s12859-022-04561-w.

[Testosterone inhibits human wild-type and chimeric aldosterone synthase activity in vitro].

Vecchiola A, Fuentes CA, Carvajal CA, et al.

Revista medica de Chile 2021; (149(11)):1539-1543 doi:10.4067/S0034-98872021001101539.

Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis.

Compston JE

European journal of endocrinology 2023; (188(3)):R46-R55 doi:10.1093/ejendo/lvad029.

Genetic Testing for Adrenal Tumors-What the Contemporary Surgeon Should Know.

Bates MF, Sorensen MJ

Surgical oncology clinics of North America 2023; (32(2)):303-313 doi:10.1016/j.soc.2022.10.007.

Bone health in childhood and adolescence: an overview on dual-energy X-ray absorptiometry scanning, fracture surveillance and bisphosphonate therapy for low-middle-income countries.

Madhuchani D, Seneviratne SN, Ward LM

Frontiers in endocrinology 2023; (14()):1082413 doi:10.3389/fendo.2023.1082413.

Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.

Tan ST, Boyle V, Elston MS

Hypertension (Dallas, Tex. : 1979) 2023; (80(7)):1517-1525 doi:10.1161/HYPERTENSIONAHA.123.21054.

Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?

Pofi R, Caratti G, Ray DW, Tomlinson JW

Endocrine reviews 2023; (44(6)):975-1011 doi:10.1210/endrev/bnad016.

Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.

Araujo-Castro M, Parra P, Martín Rojas-Marcos P, et al.

Frontiers in endocrinology 2024; (15()):1336306 doi:10.3389/fendo.2024.1336306.

Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.

Mulatero P, Scholl UI, Fardella CE, et al.

European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.

European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency.

Beuschlein F, Else T, Bancos I, et al.

European journal of endocrinology 2024; (190(5)):G25-G51 doi:10.1093/ejendo/lvae029.

Genetic testing for familial hyperaldosteronism type 1 in Aotearoa/New Zealand.

Elston MS, Tamatea JAU, King RI, et al.

Internal medicine journal 2024; (54(11)):1814-1820 doi:10.1111/imj.16511.

Decoding Monogenic Hypertension: A Review of Rare Hypertension Disorders.

Gallegos FR, Delahunty MP, Hu J, et al.

American journal of hypertension 2025; (38(6)):333-351 doi:10.1093/ajh/hpaf005.

Adrenal causes of endocrine hypertension in childhood or adolescence.

Pellegrini B, Bonaventura I, Hasenmajer V, et al.

Journal of endocrinological investigation 2025; (48(11)):2515-2545 doi:10.1007/s40618-025-02633-1.

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.

Adler GK, Stowasser M, Correa RR, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.

Glucocorticoid Remediable Aldosteronism in a Family with a Strong History of Cerebral Aneurysms and Hypertension.

Zeman J, Kamilaris C

Prague medical report 2025; (126(3)):151-154 doi:10.14712/23362936.2025.23.

Secondary Adrenal Insufficiency and Iatrogenic Cushing's Syndrome in a 13-Year-Old Male With Vogt-Koyanagi-Harada Disease: A Case Report.

Paparella R, Bernabei I, Bei A, et al.

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 2026; (40(3)):e125-e130 doi:10.1016/j.pedhc.2025.09.013.

From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians.

Murphy C, Nasomyont N, Tian C, et al.

Neuromuscular disorders : NMD 2026; (62()):106411 doi:10.1016/j.nmd.2026.106411.

Survey of Adrenal Insufficiency Management for Duchenne muscular dystrophy in Italy.

Tornese G, Wong SC, Sbrocchi AM, et al.

Endocrine 2026; (91(1)).

Prevalence and Predictors of Bone and Ocular Complications in Children With Steroid-Sensitive Nephrotic Syndrome: A Cross-Sectional Study.

Patel K, Kumar M, Singh SP, et al.

Cureus 2026; (18(5)):e109153 doi:10.7759/cureus.109153.

Liddle syndrome caused by SCNN1B mutation presenting with severe early-onset hypertension and hypokalemia in an adolescent: a case report.

Min X, Liang Y

BMC endocrine disorders 2026; (26(1)).

Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions.

Rutter MM, Crane JL, Babalola F, et al.

Journal of neuromuscular diseases 2026; 22143602261486896 doi:10.1177/22143602261486896.